Epidermal Growth Factor Receptor Clinical Trials

2 recruiting

Frequently Asked Questions

Common questions about Epidermal Growth Factor Receptor clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting

Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

Non-small Cell Lung CancerStage IV Lung CancerStage III Lung Cancer+1 more
PrECOG, LLC.538 enrolled144 locationsNCT06538038
Recruiting
Phase 2

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Taiho Oncology, Inc.220 enrolled80 locationsNCT05967689
Recruiting
Phase 1Phase 2

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Triple-Negative Breast CancerEndometrial CancerPrimary Peritoneal Carcinoma+12 more
Genmab764 enrolled67 locationsNCT05579366
Recruiting
Phase 1Phase 2

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Triple Negative Breast Cancer(TNBC)+3 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.230 enrolled12 locationsNCT05985655
Recruiting
Phase 2

Bolstering Outcomes After Induction With Osimertinib Plus Chemotherapy Through Optimized Site-Directed Primary Tumor Therapy (BOOST Trial)

Non-small Cell Lung CancerEpidermal Growth Factor Receptor
Pusan National University Hospital70 enrolled1 locationNCT07073365
Recruiting
Phase 1Phase 2

Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells

Glioblastoma MultiformeGlycolytic IndexEpidermal Growth Factor Receptor
Jonsson Comprehensive Cancer Center50 enrolled1 locationNCT06059690
Recruiting

LAT for Oligoprogressive NSCLC Treated With First-line OSImertinib

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Universitaire Ziekenhuizen KU Leuven39 enrolled1 locationNCT04216121
Recruiting

Observational Study of Afatinib 30 mg Daily

Non-small Cell Lung CancerEpidermal Growth Factor Receptor Mutation
National University Hospital, Singapore69 enrolled1 locationNCT04909073
Recruiting
Not Applicable

A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Kunming Medical University30 enrolled1 locationNCT06102928